Summit Trail Advisors’s Quest Diagnostics DGX Stock Holding History

Summit Trail Advisors’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.19M	Sell	15,051 -300	-2%	-$58.9K	0.04%	341
2026 Q1	$3.01M	Buy	15,351 +3,714	+32%	+$722K	0.04%	310
2025 Q4	$2.02M	Sell	11,637 -643	-5%	-$117K	0.03%	396
2025 Q3	$2.34M	Buy	12,280 +7,012	+133%	+$1.24M	0.03%	367
2025 Q2	$946K	Buy	5,268 +1,284	+32%	+$223K	0.02%	501
2025 Q1	$674K	Buy	3,984 +2,157	+118%	+$354K	0.02%	209
2024 Q4	$276K	Sell	1,827 -246	-12%	-$38.3K	0.01%	310
2024 Q3	$322K	Sell	2,073 -620	-23%	-$92.6K	0.01%	524
2024 Q2	$369K	Buy	+2,693	New	+$369K	0.01%	436
2018 Q4	–	Sell	-36,360	Closed	-$3.92M	–	149
2018 Q3	$3.92M	Buy	36,360 +35,795	+6,335%	+$3.93M	0.87%	25
2018 Q2	$62K	Sell	565 -23,651	-98%	-$2.46M	0.02%	281
2018 Q1	$1.77M	Buy	24,216 +8,936	+58%	+$915K	0.3%	68
2017 Q4	$1.58M	Buy	+15,280	New	+$1.45M	0.2%	101

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Summit Trail Advisors's DGX Position: Q2 2026 in Review

Summit Trail Advisors reduced its Quest Diagnostics (DGX) stake by 2% in Q2 2026, selling an estimated $58.9K and leaving 15,051 shares worth $3.19M. The position accounts for 0.04% of the portfolio, ranked #341.

Summit Trail Advisors first reported a position in DGX in Q4 2017 and has held it in 13 quarters since. The position peaked at $3.92M in Q3 2018. 1,107 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Summit Trail Advisors held 15,051 shares of Quest Diagnostics worth $3.19M as of Q2 2026.
Summit Trail Advisors sold 300 Quest Diagnostics shares in Q2 2026, an estimated $58.9K.
Quest Diagnostics made up 0.04% of Summit Trail Advisors's portfolio in Q2 2026, its #341 holding.
Summit Trail Advisors first reported a position in Quest Diagnostics in Q4 2017 and has held it in 13 quarters since.
Summit Trail Advisors's Quest Diagnostics position peaked at $3.92M in Q3 2018.
1,107 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.